Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -53.53% | 4.49% | 10.25% | 17.10% | 12.74% |
| Total Depreciation and Amortization | -19.32% | 2.33% | -4.35% | -10.20% | -18.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2,667.08% | -1.27% | 4.47% | 13.85% | -14.13% |
| Change in Net Operating Assets | -69.80% | -88.63% | -269.67% | -220.51% | 5.91% |
| Cash from Operations | -27.69% | -6.06% | -11.51% | 2.64% | 15.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 27.39% | -8.58% | 16.05% | 30.56% | 52.07% |
| Total Debt Repaid | -42.94% | -19.37% | -53.64% | -48.23% | -9.17% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.38% | -12.30% | 11.50% | 28.16% | 60.22% |
| Foreign Exchange rate Adjustments | 96.72% | -7,966.67% | -566.67% | -625.00% | -1,425.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -32.62% | -164.28% | -14.31% | 51.82% | 75.82% |